Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 42-48

  Ganjoo, Kristen N ^a   De Vos, Sven ^b   Pohlman, Brad L ^c   Flinn, Ian W ^d   Forero Torres, Andres ^e   Enas, Nathan H ^f   Cronier, Damien M ^f   Dang, Nam H ^g   Foon, Kenneth A ^h   Carpenter, Susan P ⁱ   Slapak, Christopher A ^f   Link, Brian K ^j   Smith, Mitchell R ^c   Mapara, Markus Y ^k   Wooldridge, James E ^f  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h CELGENE CORPORATION   (United States)

ⁱ Applied Molecular Evolution   (United States)

^j UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^k Department of Medicine   (United States)

more..

Author keywords

Fc RIIIa; Follicular lymphoma; Ocaratuzumab

Indexed keywords

AME 133; ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLELE; CANCER STAGING; CASE REPORT; CLINICAL TRIAL; FEMALE; GENETICS; HETEROZYGOTE; HUMAN; LYMPHOMA, FOLLICULAR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RETREATMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HETEROZYGOTE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; RETREATMENT; TREATMENT OUTCOME;

EID: 84922342194     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.911859     Document Type: Article

References (25)

1. Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 2011;117:2993-3001.
2. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical ef cacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796.
3. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma} RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122-1129.
4. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-446.
5. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism inf uences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-1114.
6. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-758.
7. Mitrovi ç Z, Aurer I, Radman I, et al. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with dif use large B-cell lymphoma. Haematologica 2007; 92: 998-999.
8. Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007;92:1127-1130.
9. Ghesquiéres H, Cartron G, Seymour JF, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not af ected by FCGR3A and FCGR2A polymorphisms. Blood 2012;120:2650-2657.
10. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced af nity for CD16 activates NK cells at lower concentrations and more ef ectively than rituximab. Blood 2006;108:2648-2654.
11. Forero-Torres A, de Vos S, Pohlman BL, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in Fc γ RIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012; 18: 1395-1403.
12. Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
13. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
14. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efcacy of re-treatment. J Clin Oncol 2000;18:3135-3143.
15. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
16. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15: 1110-1117.
17. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma:systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
18. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-4586.
19. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
20. Ghielmini M, Rufbach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the ef ect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675-1682.
21. Persky DO, Dornan D, Goldman BH, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012;97:937-942.
22. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010;95:135-143.
23. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
24. Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab:A study of dif erent schedules of administration for heterogeneous clinical settings. Ter Drug Monit 2005;27: 785-792.
25. Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73: 213-221.